Good morning, and welcome to Moderna’s First Quarter 2020 Conference Call. At this time, all participants are in a listen-only mode. Please be advised that the call is being recorded. At this time, I would like to turn the call over to Lavina Talukdar, Head, Investor Relations at Moderna. Please proceed.

Thank you, operator. Good morning, everyone. Welcome to Moderna’s conference call to discuss our first quarter 2020 business updates and financial results. You can access the press release issued this morning as well as the slides that we’ll be reviewing by going to the Investors section of our website. Speaking on today’s call are Stéphane Bancel, our CEO; Tal Zaks, our CMO; Stephen Hoge, our President; and Lorence Kim, our CFO. Before we begin, please note that this conference call will include forward-looking statements. Please see Slide 2 of the accompanying presentation and our SEC filings for important risk factors that could cause our actual performance and results to differ materially from those expressed or implied in these forward-looking statements. We undertake no obligation to update or revise the information provided on this call as a result of new information or future results or developments. With that, I will now turn the call over to Stéphane.

Thank you, Lavina, and good morning or good afternoon, everyone. Thank you for joining the call. I hope you and your families are in good health. As you know, we believe mRNA has the potential to be a new class of medicines with the opportunity to address many unmet medical needs, with medicines that have a higher probability of technical success, with greater speed of research and clinical development versus traditional medicines and with better manufacturing capital efficiency and lower cost of goods than injectable recombinants. Given the amounts of working with new technology, we have been laser-focused on managing risk: technology risk, biology risk, execution risk, and financing risk. As many of you know, 2019 was an important inflection year for Moderna. We reported clinically validating data from key programs into other modalities, prophylactic vaccines, and systemic secreted and cell surface therapeutics, data that we believe fundamentally changed the risk profile for each of these two modalities that we now call comodalities. As a result, our strategy is to double down in these two comodalities with many important new development candidates in the space. We have already announced five new development candidates in these comodalities since January 15 at the JPMorgan Conference: three new development candidates in infectious disease prophylactic vaccines and two in the systemic secreted and cell surface therapeutics modality. While we focus on doubling down in comodalities, we are still very interested in understanding the potential of our mRNA technology in our current exploratory modalities: cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, and systemic intracellular therapeutics. So when we think about the company, we basically have two distinct areas of focus. This is a significant point in our strategy. We have comodalities we want to scale and invest in exploratory comodalities that continue to be a big driver to the company’s future as we await clinical data to decide the path forward. So stepping back, I would have to share with you the progress of the company toward a new class of medicines. This is a strategic plan that we shared with you in February 2020. In the early days of the company, our goal was to enter the clinic safely. We spent years investing in developing mRNA science, formulation delivery, and manufacturing technologies. The company pivoted out of that growth phase when we entered the clinic with our H10 influenza vaccine in December 2015. In the clinic, our next goal was to learn how well our technology was working or not. We explored our technology across six different modalities. We tested 16 different molecules in the clinic in a short four-year period. In 2019, we generated important data in two of these six modalities and identified our first two comodalities, infectious disease prophylactic vaccines, and systemic secreted and cell surface therapeutics. Early in the year, we entered a new phase of the company’s development. Our goal for this next phase in our history is to file multiple BLAs while continuing our clinical programs in the four exploratory modalities and continuing to invest aggressively in early research to invent new modalities such as our ongoing collaboration with Vertex. When we first presented this plan in early February this year, we had imagined that the next phase of growth of the company would have taken us three to four years. Our vaccine against the SARS-CoV-2 virus, mRNA-1273, is a major acceleration of our company’s development. Today, we are very happy to announce that we received yesterday clearance from the FDA to proceed with the Phase II. It’s just nine days from filing our IND on Monday, April 27, the FDA has given us a green light. We intend to start the clinical trial as soon as safely possible. We’ve also announced this morning that we are finalizing the Phase III protocol. And our aim is to start dosing the Phase III in early summer 2020. This means that we have a potential for a BLA approval for mRNA-1273 in 2021. That is an acceleration of several years versus the plan we had just months ago. Moderna should be a commercial-stage company in 2021. That is two to three years ahead of our previous plans, plans we outlined just months ago. This is a unique opportunity. So we are working actively to get the company ready. To deliver on this acceleration of the company’s plan, we’re expanding our leadership team in areas where their expertise will be instrumental in allowing us to successfully file several BLAs and be ready commercially. Today, we are announcing three new additions to the leadership roles of Moderna. First, Patrick Bergstedt. Patrick joins Moderna as Senior Vice President, Commercial Vaccines. Patrick will report to me. Patrick joins from Merck & Co. where he most recently was Head of Global Marketing & Commercial Operations for the entire vaccine business at Merck. Patrick will start on June 1. Patrick led global initiatives with a focus on revenue growth and access expansion. He is a 20-plus year veteran in the biopharma industry and has held various leadership positions within infectious disease and global health at Merck in the U.S., Europe, and Asia. Second, Dr. Jacqueline Miller. Jacqueline will be joining Moderna on May 11 from GSK as Senior Vice President, Infectious Disease Development. Jacqueline joins the company from GSK where she held a variety of leadership roles since 2005. Most recently, Jacqueline was the Vice President and Head of Clinical R&D and Epidemiology, where she built and led the clinical and epidemiology research team at the first GSK vaccine research and development center in the U.S. And third, Dr. Charbel Haber. Charbel joined Moderna on April 21 as Senior Vice President for Regulatory Affairs. Charbel joined us from Biogen, where he served as Vice President, Global Safety and Regulatory Sciences since 2017. In this role, he built and led the Global Regulatory Strategy Department, the clinical trial application group, and the Medical Writing group. Prior to Biogen, Dr. Haber was Head of Global Regulatory Affairs-Immunology and Neurology at EMD Serono. I am very excited to welcome Patrick, Jacqueline, and Charbel, and look forward to their contribution at Moderna as we embark on the commercial stage phase of our company. It is a bittersweet moment to announce today the departure from the company of Dr. Lorence Kim, our Chief Financial Officer. Lorence joined the company in 2015 when the company was private. As some of you remember, it was a preclinical stage company with zero development candidates. Lorence super-charged Stephen Hoge and me and decided to leave a great job at Goldman Sachs to join us. The company is now public with 23 development candidates and preparing its first Phase III. Lorence will manage with us for a smooth transition. He will participate in Moderna's second quarter conference call in August with us before leaving the company. I am very thankful for Lorence’s contribution over the years and for the constructive discussions he and I had about entering a smooth transition. There is never a good time for leadership transitions, but the company is very well capitalized with around $2.4 billion of capital to invest to create value. We need to focus on the next phase of readiness for the company to be commercial. We have retained Russell Reynolds for the search for Moderna’s next CFO. We will focus on a CFO who has public company and commercial and global operation experience, given this is where Moderna is heading. Before I hand over to Tal for clinical updates, I wanted to take a few minutes to frame the opportunity in our vaccine modality. We believe mRNA has the potential to be a new class of vaccines, where each of the four drivers of value applies. We are very excited about the potential of our vaccines to drive this value. First, as we discussed, a very large opportunity, the ability to develop first-in-class vaccines that do not have products on the market today to protect as many people as we can. Second, a relatively high probability of technical success. As we discussed at our Vaccine Day, Dr. Andrew Lo from MIT has shown that from the start of a Phase II study, which is post the Phase I, to approval, vaccines have a 42% probability of approval. This is the highest probability among all categories of medicines in clinical trials. We think this is a very important value driver for this franchise. Further, we think an important driver is speed in the labs. Even with our platform, we can study many candidates in parallel in a preclinical setting. Most difficult development candidates can swiftly transition into the clinic, as we have shown recently with the SARS-CoV-2 vaccine, going from design of a vaccine on January 13 to injecting the first human on March 16 in as little as 63 days. Finally, we believe the capital efficiency of our platform offers significant advantages over traditional vaccines. Because the manufacturing process to make mRNA molecules is a cell-free manufacturing process, it can drive much lower CapEx versus recombinant protein manufacturing. The second dimension is the CapEx leverage across the value chain. For example, when we decided to go after SARS-CoV-2, we did not have to buy any new machinery. Our team was able to leverage existing CapEx in a matter of days. With that overview, let me now turn over to Tal.

Thank you, Stéphane, and good morning, everyone. I’ll start with a quick reminder on the data generated to date with our vaccines. In over 1,500 healthy volunteers and seven positive Phase 1 datasets to date, we’ve observed a safety profile that’s consistent with the safety of adjuvanted vaccines. I’ll start with a high-level progress update on mRNA-1273, our vaccine against SARS-CoV-2, and will give more detail shortly. As you heard from Stéphane earlier, we have the FDA clearance to move into our Phase II study, and we plan to start it shortly. This study will run in parallel with the NIH-run Phase I study, which has completed enrollment of the first three dose cohorts. Our CMV Phase II dose confirmation study is fully enrolled, and we still expect data readout to come in the third quarter of this year, despite having had some COVID-19-related disruptions. At our Vaccines Day on April 14, we announced a positive interim analysis of our Phase I study for our Zika vaccine. At the two lower doses of 10 micrograms and 30 micrograms, we achieved seroconversion rates of 94% and 100%, respectively. The two higher dose cohorts of 100 micrograms and 260 micrograms are now fully enrolled. As a reminder, we paused our hMPV/PIV3 Phase Ib study enrollment as a cautionary measure to protect children and their caregivers due to COVID-19 disruptions. Our RSV program with Merck continues. So this has been covered in detail, but just to quickly pace everybody on the same place, our SARS-CoV-2 vaccine, mRNA-1273, which was a subject of much work and discussion in the first quarter of this year, demonstrates the kind of speed that we believe the platform can provide, from first selection of a sequence by our scientists and our collaborators at NIAID on January 13 to the production of a clinical batch on February 7, 25 days later. That batch was released by February 24, and by March 4, was associated with an open IND that NIAID had filed. The strong collaboration between us and NIAID led to this trial opening within 63 days, and we’ve spoken about this before. On April 17, we were awarded a contract from the U.S. government agency, BARDA, to accelerate the development. And on April 27, we announced an IND had been submitted to the U.S. FDA for the Phase II study. Last Friday, we announced a collaboration with Lonza to manufacture mRNA-1273 at scale, with the goal of producing up to 1 billion doses a year. And of course, today, we announced the FDA clearance to start the Phase II part. In parallel, we have been working on the Phase III protocol, and we are finalizing that with an aim to start the study in the summer of 2020. The design of the Phase I study is on Slide 17. The study started as a 45-subject trial with three dose cohorts, 25, 100, and 250 micrograms, with each participant receiving two vaccinations a month apart. Phase III dose cohorts have now been fully enrolled, and the safety and immunogenicity data from them will be shared when available. The NIH is expanding the trial to include two additional age cohorts, a 56-to-70-year-old cohort and a 71-and-above age cohort. Each of these age cohorts will include three dose levels also at 25, 100, and 250 micrograms at the same vaccination schedule. In terms of the late-phase development for mRNA-1273, as mentioned before, the Phase II study is expected to start shortly. This study will evaluate the safety, reactogenicity, and immunogenicity of two vaccinations of mRNA-1273 given one month apart. Volunteers will receive either a placebo, 50, or 250 micrograms at both vaccinations. This study is meant to both increase our safety database as well as confirm the immunogenicity seen in the phase that we expect to see in the Phase I. We are finalizing, as I said, the Phase III protocol, and the study is expected to begin this summer. Last week, Moderna and Lonza announced a strategic collaboration with the goal to enable manufacturing of up to 1 billion doses a year, assuming a dose of 50 micrograms. Technology transfer is expected to begin this June, and we anticipate the first batches of mRNA-1273 to be manufactured at Lonza’s U.S. sites in July of this year. I would be remiss not to mention BARDA’s role in this. The BARDA award is allowing us to move as quickly as we are with scale-up, both internally and with Lonza. Moving on to CMV. Slide 20 reviews our late-stage development plans for CMV. As previously announced, the Phase II dose confirmation study is fully enrolled, and we remain on track for data readout in the third quarter of 2020. Importantly, greater than 70% of participants have now received their second vaccine dose. A protocol amendment was submitted to expand the timeframe for the remaining participants to receive their second dose as well. As a reminder, we plan to select a dose for the Phase III after the first interim analysis, which is the data post the second vaccination. We continue to prepare for the Phase III, which is intended to start in 2021 in the U.S. and Europe. During the first quarter of 2020, we also received constructive feedback from the Type C CMC meeting that we’ve had with the FDA. Moving on to mRNA-1893, our Zika vaccine program. Let me recap on Slide 24 the data that we recently presented at our Vaccines Day, where we reported an interim analysis of the ongoing Phase I trial. This study has demonstrated a fairly benign safety profile, consistent with what we’ve seen before for other vaccines. And at the two lower doses of 10 and 30 micrograms after a two-dose vaccination regimen, prime and boost, the seroconversion rates were 94% and 100%, respectively. These data are encouraging, and we are preparing to move forward with this program into a Phase II trial. The exploratory modalities are a critical part of our strategy, and we continue to make up a significant part of what we do in the clinic. And on Slide 26, you see a – if you scan the page, you’ll see many readouts and catalysts from each of the programs, both from our core modalities as well as the exploratory ones. With that, let me now turn the call over to Lorence.

Thank you, Tal. Let me first cover an update on the Vertex agreement. In July 2016, we entered into a strategic collaboration and license agreement with Vertex in the discovery and development of potential mRNA medicines for the treatment of cystic fibrosis or CF by enabling cells in the lungs to potentially produce functional CFTR proteins. In July 2019, the initial research term was extended by six months. Based upon promising preclinical data generated, in March 2020, we were pleased that Vertex elected to extend this collaboration for a further 18 months. Now let me turn to financial results. In today’s press release, we reported our first quarter 2020 financial results. Note that these results are unaudited. We raised approximately $550 million in net proceeds from the February public equity offering, which resulted in us ending Q1 2020 with cash, cash equivalents, and investments of $1.72 billion. This compares to $1.26 billion at the end of 2019. Net cash used in operating activities was $106 million for the first quarter of 2020 compared to $144 million in 2019. Just as a reminder, that latter number includes an in-licensing payment of $22 million, which will not recur. Cash used for purchases of property and equipment was $6 million for the first quarter of 2020 compared to $8 million in 2019. Revenue for the first quarter of 2020 was $8 million compared to $16 million in 2019. This decrease of $8 million in revenue was mainly due to cumulative catch-up adjustments resulting from changes in our estimated costs for our future performance obligations, coupled with the timing of amortization of deferred revenue due to the satisfaction of our performance obligations. R&D expenses for the first quarter of 2020 were $115 million compared to $130 million in 2019. The decrease of $15 million in R&D was mainly driven by a decrease in lab supplies and materials and clinical trial and manufacturing costs, partially offset by personnel-related costs. G&A expenses for the first quarter of 2020 were $24 million compared to $27 million in Q1 2019. This decrease of $3 million was primarily attributable to decreases in legal and other consulting and outside services spend. The net loss for Q1 2020 was $124 million compared to $133 million in Q1 2019. I’ll turn now to what we expect for the remainder of 2020. If you look at our cash flow line items, you can see our cash used in operating activities and purchases of property and equipment by quarter are laid out here. In Q1 of 2020, we used $112 million of cash on these two items, which is in line with our expectations. If you go back to Q1 2019, we used $152 million of cash on these two items. And remember again, that number included that licensing payment. Overall, you can see the decline in our quarter-over-quarter cash used for these items through Q4 2019 with a slight uptick in Q1 2020. Consistent with our initial 2020 guidance, which we issued back in November, we expect our 2020 net cash used in operating activities and purchases of property and equipment to be approximately $500 million. While we have seen parts of our spend slow down as a result of the impact of COVID-19, such as certain clinical trial expenses and laboratory supplies, we are also investing in preparedness for the late-stage development and potential BLA filing for our COVID vaccine. That results in bringing our cash flow guidance back to its original levels. We recognize that much of our COVID vaccine spend is covered by the BARDA award. Note that the award is not cash upfront but rather reimbursement as expenses are incurred. We do expect to incur significant expenses this year in relation to that BARDA award, but we expect in general a matching of expenses and reimbursements. Let’s go down next on our balance sheet strength and the composition of the $2.4 billion of cash and available funding we have to invest and create value. We ended Q1 2020 with cash, cash equivalents, and investments of $1.72 billion. On April 16, 2020, we entered into an agreement with BARDA to accelerate development of our mRNA vaccine candidate against the novel coronavirus for funding of up to $483 million, of which $430 million has been committed. Additionally, we are fortunate to have established strategic alliances with private and government-sponsored organizations, including the Bill and Melinda Gates Foundation, DARPA, and another BARDA award comprising additional available funding of $180 million. Together, this creates multiple years of cash runway, considering the cash guidance that we shared today, and a strong ability to invest for the long run in many aspects of the business. The next slide shows our pipeline and the programs through the various phases of development with a snapshot here. But before I turn it back to Stéphane, let me just reiterate an important point from my announced departure this morning, which is that I expect to seamlessly transition my responsibilities through August. But I’ll make a brief remark now. First of all, I’m so grateful to have been invited to be a part of this company, what an opportunity to contribute to Moderna’s mission of turning mRNA into a new class of medicines. I joined the company six years ago at a time when this story was nascent and the future was full of unknowns. I’m leaving now as the company has multiple BLAs on the horizon with 23 important new potential medicines in the pipeline and I believe many more to come. We’ve invested heavily in the platform to establish the scientific foundations of this new class of medicines, and the team is growing with unbelievable new talent. I’m personally most proud of the financial foundation we’ve built to enable the company to invest appropriately in the business. It’s been energizing and motivating to partner with Stéphane, the Board, its executive team, and the passionate Moderna employee base. For me, I’m going to take the next step in my career, which will be to stay close to innovation in biotech, but not as a company executive. I look forward to sharing more about these plans at an appropriate time down the road with many of you on this call. And with that, I’ll turn it over to Stéphane for closing remarks.

Lorence, thanks again for your remarks. Having you as my partner for those six years has been quite an incredible ride. On Slide 34, let me close by giving you a quick update on where the company stands today, starting with our pipeline. It’s exciting to see that today we have two candidates for which we are preparing for Phase III, our CMV vaccine and our SARS-CoV-2 vaccine. We have now six candidates that are either in Phase II or preparing for Phase II, 12 Phase I programs, and 11 positive Phase I results. What an acceleration since our IPO in December 2018. Our programs are very exciting. We have seven first-in-class vaccines, where there are no approved vaccines on the market against those viruses. Most of these vaccine candidates have multi-billion dollar annual peak sales opportunities. As we shared at our Vaccine Day presentation, we believe our innovative vaccines are going to be a very large business for Moderna with long-term annuity life opportunities at a high EBIT margin. We also have five exciting immuno-oncology programs that are already in the clinic, all combined with a commercial checkpoint, four rare disease programs, and two autoimmune disease programs. The company has never been stronger and looks at formations. We have now dosed more than 1,900 healthy volunteers and patients in our studies. The team is strong and getting stronger every month. We now have more than 900 employees who care deeply about our mission and are proud and energized by our progress and the meaning of our work. Last week, with the Lonza agreement, our manufacturing capabilities have changed leagues. We not only have a fully integrated GMP site in Massachusetts, many of you know and have visited, but we’ve added a strategic partnership with Lonza that can enable us to manufacture up to 1 billion doses annually for the vaccine against SARS-CoV-2, but also other products in our pipeline as we need to. We have great partners with AstraZeneca, Merck, and Vertex. I am very proud of the scientific progress that the team of Stephen Hoge and Melisa Moore have made in the work with Vertex over the last few years. We are very pleased that Vertex decided to expand the relationship with Moderna. But we’re also very thankful for a partnership we’ve had over the years with BARDA, DARPA, CP, and the Gates Foundation. And of course, we are very thankful for the latest partnership with BARDA, $483 million, to enable us to conduct the right clinical study as fast as we go, while of course focusing on safety first for the SARS-CoV-2 vaccine. We are well-capitalized with up to $2.4 billion to invest in the business and continue to build the leading mRNA company in the world. We are very thankful for our investors for their trust and partnership as we build this unique company. We are energized by the opportunity ahead of us to build a new class of medicines. We are currently accelerating our development pipeline and readying the company to potentially file its first BLA for mRNA-1273, which will be, as you can appreciate, a historic moment for the company. We’re investing in the processes to get us there, to establish the right foundations for potentially many additional BLAs in the future, starting with the Zika vaccine and CMV vaccines behind the SARS-CoV-2 mRNA-1273. We are already scaling up the organization to address the need to supply up to 2 billion doses for the potentially first vaccine mRNA-1273. All those efforts, investments, and processes will be very enabling for additional vaccines and therapeutics to come. I have never been as excited and optimistic about the future of Moderna in the last nine years. We are humbled and excited by the opportunity to bring forward a new class of medicines for patients. That has been our North Star since we started the company. I would like to thank the great team of Moderna employees working very hard every day, literally many of them seven days a week now since January to fight the SARS-CoV-2 virus. I’d like to thank the many people who participate in our clinical studies, including patients, healthy volunteers, physicians, and nurses. I’d like to recognize all our partners that have worked with us to share our vision and help us achieve this vision to help patients. With that, we are now happy to take any questions. Operator?

Your first question comes from Matthew Harrison of Morgan Stanley. Please ask your question.

Great. I guess, first, you’ve highlighted the 50-microgram dose on the SARS-CoV-2 vaccine. Dr. Fauci in his interview also talked about good responses in low doses in animals. Can you just talk about your confidence in being able to move forward and elicit the right kind of immune response with the low dose as opposed to the other doses that you’re testing? And then, secondly, can you just update us on where the field is and figuring out what neutralizing antibody titers are and if you think they’ll be available by the time you report initial data from the Phase I study? Thanks.

This is Tal. Let me take that question. Two spot-on things that we’re looking at. So first of all, 50 micrograms is our current best guess. This is short of data and is based, as you’ve seen Tony Fauci’s remark, on what we expect the platform could deliver. That being said, the final dose selection will really be a factor of three elements. The first is the overall sense of a dose response of how much more do you get as you go up in dose. Because in the case of a pandemic, we obviously need to balance this with having enough doses available. So you don’t want to unnecessarily overshoot. The second element is an understanding of what that dose could mean as you compare it to convalescent serum. There’s a lot of work being done on assay validation, and I’ll get back to that in a minute, to understand what any given level of antibodies mean. The last element that I think will enable us to connect the dots is understanding the performance of the vaccine in additional animal models of SARS-CoV-2 and then seeing what levels of titers we get commensurate with the expected ability to protect those animals. The higher the species, the more reliable that data is. Ultimately, what we care about is being able to connect the dots for human disease. So long story short, it’s a best guess estimate for now and based on the emerging data, and we will continue to refine it as more data comes in. Your question about the right kind of immune response. Look, I think the data we’ve seen to date, both across the clinical trials and across the experience that we have in the preclinical models, across the board, every trial has routinely reported neutralizing antibodies as the measure of immunological success. If you think about the scientific-first principles of how mRNA technology presents an antigen from within the cell and mimics the instruction set that a virus would otherwise give the cell to make an antigen, we get the right kind of immune response, however we want to characterize it: neutralizing antibody in terms of Th1 versus Th2, etc. The emerging data that we’re seeing preclinically with mRNA-1273 is all consistent with that. Your final question on neutralizing antibodies, yes, those assays are being stood up as we speak. They’re being validated. They’re being transferred to commercial vendors. The NIAID is actively looking at, in parallel with the simpler types of binding antibodies we expect to be able to report, both kinds of data when we see the data from that Phase I.

Your next question comes from Cory Kasimov of JPMorgan.

I’ve got two of them for you as well. So I guess, first, can you talk more about what the Phase III COVID vaccine design might look like? There’s, obviously, nothing traditional about this program. So how should we be thinking about the endpoints interim analysis and the amount of follow-up you think you need for either emergency use authorization or full approval? And then my second question for you is regarding COVID – also regarding COVID-19. There have been some conflicting reports out there on emerging mutations with the virus. I’d be very interested to hear your views on this and what it could potentially mean for the effectiveness of your vaccine.

Thanks, Cory. This is Tal. I’ll take those questions. So look, the Phase III design, let me make a couple of points. Any pivotal trial in order to demonstrate efficacy as well as safety has to be placebo-controlled and large enough so that among the people that you will vaccinate, there will by chance occur cases, right? And so it’s a case-driven design, and you set your statistics based on what you expect to see and how many cases you expect to see in the placebo and the number of fewer cases do you expect the vaccine to demonstrate. Now any such trial to be effective depends on three things: how big it is when you start, how good are you at predicting the attack rate in the population that you vaccinated, because if it’s case-driven design, then we can vaccinate a whole lot of people. But if they end up for the months to come not being exposed to the risk of an infection, then we won’t know whether the vaccine worked. The third element is how good our vaccine is, because the higher the point estimate for the vaccine efficacy, the clearer the results are and the sooner you can find them. Somewhere between those parameters, we are going to have to have a conversation. It’s ongoing between us, our collaborators at NIAID, at the NIH, and ultimately, the FDA. The length of follow-up here and how soon can we see the data, I think, is a function of all those design elements as well as where you sort of set the bar for cases and what the expected benefit is. Now you asked an interesting question on where does EUA come into this and where does approval? What type of interim data one could expect. So I think if – as you get closer to it, my sense is that we’re not looking at a binary event in the sense that one day we know nothing, and the next day it’s suddenly available for everybody. I think as we learn more about the potential benefits first based on Phase I and II and potentially surrogate data in animal models, and an understanding of what those levels could mean from convalescent serum, we will gain more confidence in terms of the potential benefits of this vaccine. We will still not be talking about an approval, and we will not have a full safety database. But you start to generate an anticipation of potential benefit. In the context of a raging pandemic, I think that’s important. The next step of data is then to get a sense that the vaccine is safe when given to a larger group of individuals, both healthy people and those who are older with comorbidities. We need to go and build that safety database in the appropriate placebo-controlled setting. The final piece is then to actually demonstrate clinical utility benefit, and that requires to have an endpoint that’s meaningful. I think the two endpoints that are relevant for thinking about a pivotal trial are going to be COVID-19 disease, however you define a disease, the appropriate symptomatology, severity, and having a microbiological confirmation. Of course, infection per se is also a relevant endpoint because we know that asymptomatic people, even if they are themselves asymptomatic, can prevent infection, and then being fixed will result in a population-wide benefit. So there’s a benefit to society here of preventing infection even if it's less so to the individual vaccinee. Between the disease endpoint and infection endpoint, I think that’s where you’re going to see the pivotal trials in the space emerge. I hope that answers your question on the design. As we get closer to it, we lock it down with the NIH and the FDA, we will, of course, be describing it to the public. Your question regarding the emerging mutations. We’re all following that closely. I will make two points here. Number one, so far from what we’ve seen, none of the mutations that have been described are expected to significantly interfere with binding or neutralizing activities of antibodies generated against the full-length spike protein. Here, I’d remind you that our mRNA-1273 actually encodes for the full-length spike protein. I think the mutation that everybody kind of saw last week had to do with potentially increased transmissibility, but that mutation doesn’t necessarily alter the critical neutralizing binding domains as we understand them. We’re clearly watching this area closely, like everybody else, to assess the potential impact. Secondly, I’d say with a more long-term vision, should such a mutation arise and be relevant for the immunity of the population that’s been exposed or the effectiveness of any vaccine, I would contend that, actually, our platform is going to be uniquely suited to address that for two reasons. Number one is, as we’ve demonstrated, you can move very fast based on just understanding the sequence of a new mutation, and you immediately generate a vaccine against it. But importantly, as you look to the future, one could envision a world where if we’ve demonstrated efficacy and benefit against this virus in the appropriate randomized-controlled trials, if there’s a slight mutation and you alter the vaccine to kind of chase the virus, the path to approval and expected benefit for the next one should be much quicker. You can think of the way the world has evolved to deal with flu mutations, whereby as soon as there’s a new sequence, that sequence is put into production, and millions of doses of vaccines are generated. You don’t need to replicate the entire Phase I, II, III development path every time there’s a minor mutation once you’ve established the platform. So as I look to the future, I think we’re in a very good place from the fundamentals of our platform to envision that sort of response to any rising mutations.

Your next question comes from Ted Tenthoff, Piper. Please ask your question.

Great. Can you hear me okay?

Yes.

Great. Sorry about that before. And thank you for all of the hard work. It’s been just an incredible run during the last couple of weeks and the company has really risen to the challenges. Lorence, it’s been so nice working with you, and I’m wishing you all the best too. So my question actually has to do with CMV. I know you guys have talked about the challenges just with getting the final data sets and the final processes and all those things. I wanted to see if there’s an update on that and whether or not there are any changes to the expectation for data in the third quarter. And also, how this general progress and investment in the vaccine platform will really help what you’re doing in CMV. Thanks so much.

Thanks, Ted, for the kind words. This is Tal. Let me try and take maybe both of those questions, and Stephane can add on. On CMV, I believe we remain on track, and you can do the simple math here. If we’ve already vaccinated over 70% of people with the second dose, and it’s that critical post-second dose interim analysis that should confirm our dose for Phase III. If you recall the data from the Phase I, with much smaller numbers of subjects, we had pretty tight error bars and a pretty good understanding of the dose response curve. Now with the much larger study, even if it ran into some sort of difficulty because of COVID-19, we’re going to be more than powered to understand the immunogenicity. The size was really driven not just by the need to understand immunogenicity, but also to validate the safety profile that we see here. So I’m confident that with the numbers of people that we managed to get into the second dose and the amendment of the protocol for the remaining less than 30%, that we will stay on track, as we’ve discussed before, to have the data and be able to move on. Our plans for Phase III continue and remain fully on track for CMV. Your question on how it’s preparing the platform. I’ll give you a sort of brief answer from the approach of maybe medical and development, and then I’ll let Stephane talk as it relates to the company moving towards its commercial life phase. The COVID experience is doing really three things for us. It is accelerating our understanding of the safety and immunogenicity at a much wider level for the platform, sort of the leading edge of data, if you will. I expect that the ability to run a large placebo-controlled trial and expand the safety database at a much more rapid manner than we had so far in Phase I will be informative for all of us as to the performance of this platform. Here, I speak as a Chief Medical Officer with a keen eye on the safety profile of our platform. So far, we’ve seen nothing unexpected, and it’s all been consistent across the application. But of course, a database of 1,500 subjects will benefit greatly when we go into thousands with COVID. The second element has to do with expanding our capabilities, building up a development team that can integrate and build a BLA file, building up our competencies on the regulatory front, the pharmacovigilance front, etc. All of that ahead of a large Phase III effort on CMV, I think, is a tremendous benefit for us. I’ll let Stephane speak to all the other elements that indicate this is accelerating the progress of our company.

Thanks, Tal. I would just add a few things, and I think Tal started to allude to it, which is the power of our platform, which really creates some powerful network effects. If you take an example of something new we shared today, we had a positive Type C meeting last quarter around CMV for CMC support manufacturing. As you can appreciate, this dialogue with the agency around CMV Phase III is going to be very instrumental in helping us on the Phase III for the SARS-CoV-2 mRNA-1273. Because of the urgency that the agency has, we’ve had an amazing dialogue with the FDA. The responsiveness, seven days a week, very engaged, very willing to find every way to shape a deal process without making any shortcuts on safety, obviously. So for this BLA process, we should be able to go through in the next months, both on the clinical side and also on the manufacturing side. This access to the agency, with the ability to ask questions and get clarifications quickly will really help us build that capability within the team but also all the digital infrastructure in terms of data gathering, which is critical on clinical and CMC. You’re going to be able to use that very quickly on Zika, on CMV, and I think that’s going to be very powerful. The network effects, I think, are sometimes underappreciated because most companies, as you know, do not have platforms, whereas here, because mRNA is an information molecule, there’s really an ability to make Moderna very robust and take it to the next level. So that’s what we do on the SARS-CoV-2 BLA-wise can be replicated much faster and more strongly on Zika, CMV, and all the other programs. I think it will be the same things around the commercial. With the arrival of Patrick, we are going to build very rapidly in our commercial infrastructure. We’ll give you updates on that in the coming months. But as you can appreciate, all that work that’s happening very quickly on COVID will help us on the other products. It is also a competitive branding standpoint because the Moderna brand has been transformed in the last few months by the results that the team has been able to accomplish. First of all, the product at the center of advancement at the clinical level. So I think the momentum of Moderna is going to be extremely strong and extremely enabled by the SARS-CoV-2 verifying process.

Your next question comes from Yasmeen Rahimi at Roth Capital Partners. Please ask your question.

Hi, team. Thank you for the continued amazing progress that you’re making day over day. Two quick questions for you. The first question is related to how you are defining age cut-off. In the Phase II, you mentioned there will be a cohort of patients who are 55 and above. Is there maybe a range above which you’re not going to be going after? And then is there going to be a cohort among the Phase II and as you’re thinking about Phase III that are healthy but are at highest risk given that they may have obesity or cardiovascular disease? How are we thinking about this patient population that are at the highest risk to incorporate that into the Phase II and Phase III enrollment? And then the second question is in regard to manufacturing. If you could help us understand, what is the single largest unknown when it comes to scaling up mRNA therapeutics?

This is Tal. Let me start by answering the clinical ones, and then I’ll let Juan take the manufacturing question. In our Phase II, there is no upper limit. I think above 55. You’ve seen the NIH Phase I sort of parse it out a little bit more finely. I think, for us, we’re going to take all comers above 55 with no upper age limit. In terms of your question on cohorts at higher risk for disease should they get infected, this relates to both the elderly and people with distinct comorbidities. As we build the safety database, we obviously need to get there, but do so responsibly. I think the Phase II initial sort of expansion into larger numbers is going to be people that do not have a high risk of disease should they get infected. In the Phase III, we will clearly then open it up, and we will do that in a manner that’s responsible and takes the appropriate interim looks to make sure that we expand into the population who needs it the most in a careful way. This is an ongoing discussion, obviously, between us, NIAID, and FDA on how to best achieve that goal. Let me let Juan take your manufacturing question.

This is Juan Andres. Let me take the second question that you have. Lonza brings an incredible track record in supporting and manufacturing products worldwide. Lonza’s capacity, together with the capacity that we have at our site in Massachusetts and the capability, will be a great help for Moderna in scaling up and producing the quantities. We are going to manufacture together with Lonza the formulated bulk, and I expect that we will have more partnerships with existing CMOs once we’re finished in distribution, and if needed, with new ones. Thank you.

Yes. And maybe Yasmeen, just to add something. We are extremely fortunate to have Juan and this leadership team. As you know, he and the team have all come from large organizations. They have managed very large manufacturing complex organizations. They have a lot of experience. They know that every extra million doses we can get out of our system will help a lot of people. So I’m very thankful for the team. They are literally working seven days a week, pulling all-nighters to shave every day we can so that we can maximize the mostly output of the system, and I’m tremendously thankful for them.

Your next question comes from Geoff Meacham with Bank of America. Please ask your question.

This is Alec on for Jeff. Lorence, we’re sorry to see you go, but I assume you’re moving on to bigger and better things. My question is on capital allocation in the near term. You reiterated your 2020 expense guidance. But I was hoping you could give a bit more color on the givings and takings within that vis-a-vis OpEx versus CapEx. How much manufacturing build-out and commercial readiness activities for COVID-19 are reflected within that? My second question is on the commercialization front. Do you intend to take the vaccine forward yourselves? Or do you think it will take partnering to deliver that at scale? Or would the U.S. government potentially step in as well? Any color you can give here. If there’s some historical context you could point to, that would be great.

Alec, it’s Lorence. Let me handle the financial question. With respect to the guidance and the components, so as I mentioned around sort of the pre-COVID business, if you will, I’d mentioned that we’re seeing a bit of a slowdown in expenses related to lab work and some clinical trials, as we’ve noted. Those expenses will be coming down relative to what we thought when we originally set out guidance. The offset is investments that we are making to be ready for all that’s coming down the road. We’ve mentioned this rapid acceleration of the COVID vaccine timelines, and there’s a lot that we need to do at the company to be ready for potentially being commercial in 2021. Those offsets, we will continue to update you all as we scope those investments moving forward. With respect to CapEx, it is not a huge component right now of the anticipated budget, mainly because of the leverage we’ve got in the platform and the benefit of having a great partner like Lonza onboard. We’ll continue to update that guidance should anything change. The last thing I would just reiterate is that there is substantial OpEx expected with respect to the COVID vaccine work being funded by BARDA, the clinical development at scale-up. But that will be paid for by BARDA reimbursed on a very rapid cycle time. That’s why I mentioned there would be this matching of expense and reimbursement throughout the course of the year that would substantially offset.

Yes. Thanks, Lorence. And Alec, on commercialization, as you can appreciate, as we’ve said before, with the case of CMV, we do not anticipate having the capability and investing to sell the products in our complete countries. For SARS CoV-2, I think it’s important to think about the product in two different time horizons. There is a pandemic phase, in which obviously, we all are. We believe, as a company, that there’s some opportunity for this product in the pandemic phase because we do not believe this virus is going away. For the pandemic phase, it’s going to be mostly a partnership with governments. In this case, you don’t have to manage complex sets of potential buyers, because we’re going to be, as we discussed, at the global level across the industry, we’re going to be supply constrained for some time, which is why, as we’ve said publicly many times, we are working for everybody with the vaccine. We are hoping that many vaccines are going to be finished. Because, if you think about it, there are very few companies that have both the manufacturing scale that is required for the task ahead and are already in the clinic, meaning they can have a short to midterm impact with our vaccine. There are, in my opinion, just a couple of companies that have those two things. If you think about it in a supply-constrained world in 2021, it’s going to be mostly partnering with governments. They will do the allocation in the different geographies. We do not intend, for example, in the U.S., to decide who gets the vaccine. That will not be appropriate. So we intend to continue our partnership with the U.S. government that we’ve already done with NIAID. Dr. Tony Fauci’s team has worked with us for a few years, as you know. More recently, we are partnered with BARDA, and eventually, I assume the CDC, to be able to supply the U.S. government the doses for them to decide the allocation that makes sense for the country.

Your next question comes from Alan Carr of Needham & Company. Please ask your question.

Thanks for taking my questions, and congratulations on progress. I got a couple of them. In your increased focus and success with vaccines, are you able to accelerate? What sort of extra emphasis are you putting on these early-stage vaccine programs? Can you give us an update on 1345 and 1893, your RSV and EBV programs that are internal? How are those moving along? I know you don’t give high-res info and timelines, but to the extent you can. Then the other question is around your COVID-19 program. To what extent is it feasible to have even an interim analysis of your planned Phase III trial in 2020?

Let me start, maybe with your first question on EBV and RSV in pediatric. As you know, we do not guide on programs' timelines. The team is working on advancing those important vaccines as fast as possible. But we have given no timelines and will not give timelines. On the retail, as you appreciated over the quarters, to give timelines, when we get closer to kind of late-stage development, especially with the SARS-CoV-2, given the pandemic and the suffering around the world, we think it’s important to communicate our best plans. I hope everybody can appreciate that when we say we aim to start a Phase III early summer, this is the best possible physical plan. Fifty things can derail that. But for the early programs, we are not communicating. Tal, do you want to take the COVID interim data question?

Yes. It’s a good question. I believe we should be able to have a sense of the cases and a potential early look by the end of the year. But again, that is a function of how soon can we start, how big the trial is, and how good we are at immunizing people who are then at risk for cases occurring, since as I mentioned, it will end up being a case-driven design to analyze it. We’ll share the details on the expectations once we lock down the design with our partners and vet it with the agency.

Your next question comes from Gobind Singh of BMO. Please ask your question.

This is Gobind on for George. Two on 1273. The first one would be, can you help us understand if there are any profit share agreements in place? Were there any other parties, including the NIH, around the vaccine? Just how do you guys see the commercial landscape evolving with so many other vaccine candidates in development? And then just to follow up, maybe with the NIAID’s comments about their preclinical results that they saw. I understand they’re probably doing their studies separate from you guys. But maybe you can help us understand what kind of preclinical results you’ve seen and when might this data be presented?

Yes. So it’s Stephane. I’m going to start, and then the team might think of issues I drop. It’s pretty – as Tal said, there’s preclinical work being done, both in the labs and at NIAID, both with Dr. Tony Fauci’s team. As soon as they have a body of data that makes sense and is complete and holistic, we intend to publish that work. As soon as it’s public, you’ll be aware. In terms of the profit share, we have not disclosed previously any arrangement, so I will not comment on that. As for your other question on the commercial landscape, as I briefly mentioned a few minutes ago, there are 100-plus vaccine candidates being worked on around the world. The important things to consider are manufacturing scale and where those projects are in research and development. As I said before, I believe that the projects that are at this stage in research with a group that doesn’t have the ability to produce tens of millions of doses ramping up to hundreds of millions per month will not have a significant impact on this pandemic. If you use those two as a screen, that’s what we do. I think we end up with very few players that have the chance in the 2021 timeframe to have any impact. Obviously, as always in drug development, not every candidate is going to get to the finish line. I can see that some early projects may not succeed in investing capital and talent for something that might have no commercial end. While there are many players in the starting line, I sense very few will reach the finish line with manufacturing scale that matters.

Your next question comes from Justin Kim with Oppenheimer. Please ask your question.

This is – it’s actually Hartaj on for Justin. So one thing first, Lorence, thank you so very much. It was a real pleasure working with you. I look forward to seeing you again sometime in the future. And then secondly, just to Moderna for all the work that you’re doing. I think a lot of people really don’t understand just the compression of the timelines that you and the government are engaging. It’s really a thing of beauty. So two questions. One is manufacturing and a second on regulatory strategy worldwide. So on manufacturing, if you can just talk a little bit about going from clinical to commercial batches. I know you’ve talked about going from millions, tens of millions to now a billion with Lonza. Can you just talk broadly about the timing? When can you go from that clinical? I know you’ve mentioned that Lonza will start manufacturing first batches in July. How does that map against the BLA that you’ll be starting to file? Then, secondly, on regulatory strategy. Japan just approved remdesivir. I guess the EU is going through an approval process for remdesivir. How are you thinking of the worldwide approval strategy aside from the U.S. where I assume you’ll file the BLA towards the end of the year?

So Hartaj, let me start quickly on manufacturing. We have not done and have shared precise output per month. What we’ve said is that given we’re ramping up both Norwood, which we said could do up to 100 million doses per year at the 50-microgram dose, and then the Lonza site. As you appreciate, basically, every month this year, every month next year, the output per month is going to increase. The team is working as hard as they can because they do understand, trust me, that every extra 100,000 vials we get out of the system will protect more people and slow down the spread of this virus. It’s not a linear process where you start now at 100 million doses per month, of course not. It’s just going to be an acceleration process, which is why this dialogue with the government regarding allocation. We’re going to be hand to mouth for quite some time. As soon as product is made and QC’ed, we will go to the government, and then they’ll decide how they allocate it. Tal, do you want to take the regulatory question maybe?

Yes. Thanks, Stephane, and thanks, Hartaj, for the question. Look, we’re in active dialogue now with the regulators beyond the U.S. I think having the partnership with Lonza is a huge enabler to envision the ability to scale up and eventually supply the vaccine on a global footprint to those who need it the most. That will take shape over the coming weeks and months. The expectation I have is that we will do more than one trial to demonstrate the benefit. That being said, at a certain point, we will obviously have data, both potential benefit and ultimately for benefit. By and large, that data should be applicable for filing in other territories. We’re actively mapping it out, and our intent is absolutely to make this vaccine available to those who need it the most.

There are no further questions at this time. Presenters, you may continue.

Thank you so much, everybody, for participating, and we look forward to talking to you, hosting you at the latest on June 2 for the Moderna Science Day. Stephen and his team will host. Thank you very much. Have a good day and stay safe. Bye-bye.

Ladies and gentlemen, this concludes today’s conference call. Thank you for participating. You may now disconnect.